Please provide your email address to receive an email when new articles are posted on . Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung ...

A recent analysis found that neoadjuvant chemoimmunotherapy led to higher 2-year overall survival and disease-free survival (DFS) rates than neoadjuvant chemoradiotherapy in patients with locally ...

The foods you eat during chemoimmunotherapy may largely depend on how you’re feeling. “When you’re feeling generally well, you’re encouraged to incorporate healthy eating practices,” says Vanessa ...

Patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 scores 1%-49% who received chemoimmunotherapy regimens seemed to do better than patients treated with immunotherapy alone, according ...

Please provide your email address to receive an email when new articles are posted on . PFS rates at 30 months appeared similar between patients in the radiation and observation groups. Longer ...

Chemoimmunotherapy shows promising long-term benefits for resectable NSCLC, with 65% five-year progression-free survival and 69.3% overall survival. Protocol adherence significantly improves outcomes, ...

Nicole Lamanna, M.D.: Danise, when you first started therapy—and it was my colleague who actually initially treated Danise—what did Dr. [Mark] Frattini, M.D., Ph.D., talk to you about, in terms ...

Experts deliberate on the optimal timing of chemoimmunotherapy and if it should be before or after surgery. David Carbone, MD, PhD: Dr Dietrich, do you think it’s fair to say that, given the fact that ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery for patients with aggressive stage III non-small cell lung cancer that is ...

Compared with chemotherapy, neoadjuvant chemoimmunotherapy led to better event-free survival and complete responses but not overall survival in patients with resectable non–small cell lung cancer ...

One of the potential risks of chemoimmunotherapy is myelo- and immunosuppression and, in its consequence, the onset of myeloid malignancies (acute myeloid leukemia [AML] and myelodysplastic syndrome ...

Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children's Research Hospital clinical trial that included a novel monoclonal antibody produced ...